BiotechTube

LY2495655 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Muscle Weakness

Conditions

Muscle Weakness

Trial Timeline

May 1, 2012 → Dec 1, 2013

NCT ID
NCT01604408

About LY2495655 + Placebo

LY2495655 + Placebo is a phase 2 stage product being developed by Eli Lilly for Muscle Weakness. The current trial status is completed. This product is registered under clinical trial identifier NCT01604408. Target conditions include Muscle Weakness.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT01604408Phase 2Completed
NCT01369511Phase 2Completed
NCT01341470Phase 1Completed

Competing Products

20 competing products in Muscle Weakness

See all competitors
ProductCompanyStageHype Score
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
51
Enfortumab vedotin + PembrolizumabAstellas PharmaPhase 2
52
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
52
Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
77
EperisoneEisaiPhase 3
77
HRS-9190Jiangsu Hengrui MedicinePhase 1
33
HRS-9190 for InjectionJiangsu Hengrui MedicinePhase 1
33
Botulinum Toxin Type AAbbViePhase 3
77
BOTOX + PlaceboAbbViePhase 3
77
BOTOX + PlaceboAbbViePhase 3
77
BOTOX + Placebo for BOTOXAbbViePhase 3
77
BOTOX + PlaceboAbbViePhase 3
77
Durvalumab + Tremelimumab + Enfortumab VedotinAstraZenecaPhase 3
77
Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)AstraZenecaPhase 3
77
Durvalumab + OleclumabAstraZenecaPhase 1
33
AZD4547 + MEDI4736 + Olaparib + AZD1775 + Vistusertib + AZD9150 + SelumetinibAstraZenecaPhase 1
33
Durvalumab + Cisplatin + GemcitabineAstraZenecaPhase 3
77
Durvalumab + BCGAstraZenecaPhase 3
77
Durvalumab + MonalizumabAstraZenecaPhase 2
52
Durvalumab (Imfinzi) + TremelimumabAstraZenecaPhase 2
52

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85